Gyroscope Therapeutics is developing gene therapy beyond rare disease and using it to treat a leading cause of blindness, dry age-related macular degeneration (dry-AMD). Dry-AMD is the leading cause of permanent vision impairment for people aged 65 and over and there are no approved treatments.

Research suggests that when a part of our immune system, the complement system, is overactive it causes inflammation that damages healthy eye tissues.

Our investigational therapy, GT005, is designed to restore balance to the complement system. The goal is to slow, or possibly stop the progression of dry-AMD. Patients in our Phase I/II clinical trial receive a single dose of the therapy through a one-time procedure into the back of their retina.

Syncona, our lead investor, helped us create the only retinal gene therapy company to combine discovery research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London, UK, with a U.S. headquarters near Philadelphia, PA, we are building a pipeline of medicines, surgical procedures and delivery devices to preserve sight and fight the devastating impact of blindness. For more information go to:

Contact Gyroscope Therapeutics
Visit Website